Emergent BioSolutions Inc. (EBS)
Upgrades & Downgrades
Latest EBS news
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
29 June 2022
Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contractin...
Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance
27 June 2022
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review
24 June 2022
Emergent BioSolutions Inc. EBS, +7.19% said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aime...
Two Pharma Companies That Will Profit From The MonkeyPox Outbreak
12 June 2022
The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosoluti...
7 No-Brainer Biotech Stocks to Add to Your Buy List
9 June 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first ...
7 Monkeypox Stocks That May Take Off in Q2
9 June 2022
SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared ...
Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract
7 June 2022
Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for te...
Contract manufacturer Emergent says J&J breached vaccine contract
6 June 2022
Contract manufacturer Emergent BioSolutions Inc said on Monday U.S. drugmaker Johnson & Johnson had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the compan...
Emergent BioSolutions to Participate in Investor Conferences
2 June 2022
GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following in...